AGONIST PRAMIPEXOLE VS LEVODOPA ON MOTOR COMPLICATIONS IN PARKINSON'S DISEASE

激动剂普拉克索与左旋多巴对帕金森病运动并发症的影响

• 批准号: 6297969
• 负责人: DAVID G. STANDAERT
• 金额: $ 0.06万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297969
• 关键词: Parkinson's disease; antiparkinson drugs; blood chemistry; clinical research; clinical trial phase I; dihydroxyphenylalanine; dopamine agonists; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; mental disorder chemotherapy; mental health epidemiology; neural degeneration; psychomotor function; quality of life; questionnaires; vital statistics

The purpose of this study is to compare a dopamine agonist pramipexole with carbidopa-levodopa in the initial treatment of early, symptomatic Parkinson's disease. Parkinson's disease is a very difficult to treat neurodegenerative syndrome and carbidopa-levodopa, a mainstay of treatment, is associated with adverse neurologic reactions. This is a multi-center, randomized, double-blind, parellel, placebo-controlled trial of a total of 300 patients to compare the 2 therapies. The primary outcome measure is the time until the first dopaminergic motor complication, and secondary measures include quality of life and the requirement for supplemental study drug and additional carbidopa- levodopa.

本研究的目的是比较多巴胺激动剂普拉克索 卡比多巴-左旋多巴用于早期、有症状的初始治疗 帕金森病。帕金森病是一种非常难治疗的疾病 神经退行性综合征和卡比多巴-左旋多巴（卡比多巴-左旋多巴）是 治疗，与神经系统不良反应有关。这是一个 多中心、随机、双盲、平行、安慰剂对照 总共 300 名患者进行了试验，以比较两种疗法。这 主要结果指标是第一次多巴胺能运动的时间 并发症，次要指标包括生活质量和 补充研究药物和额外卡比多巴的要求 左旋多巴。